息风通络化瘀汤对高血压病超敏C反应蛋白及血压的影响

目的观察息风通络化瘀汤治疗高血压病患者的临床疗效及其对超敏C反应蛋白(hs-CRP)水平的影响。方法将66例高血压病Ⅱ～Ⅲ级(肝阳上亢兼血瘀证)患者随机分为治疗组与对照组,两组均服依那普利联合氨氯地平,治疗组加服息风通络化瘀汤。比较两组血压下降情况及hs-CRP水平变化。结果两组治疗后降压效果及hs-CRP的降低程度均较明显,而以治疗组改善程度更佳。结论息风通络化瘀汤治疗高血压(肝阳上亢兼血瘀证)疗效确切,并能更好地降低hs-CRP水平。

息风通络化瘀汤对高血压病及其心血管危险因素干预作用的临床研究

目的观察息风通络化瘀汤对高血压病(肝阳上亢兼血瘀证)的疗效及其心血管危险因素干预的影响。方法高血压病患者100例,随机分为两组。对照组应用依那普利、氨氯地平降压,洛伐他汀胶囊降脂;治疗组在此基础上加服息风通络化瘀汤。评价治疗后的血压下降情况及其心血管危险因素的变化。结果治疗组治疗后血压、血脂及超敏C-反应蛋白水平均降低,与对照组比较差异有统计学意义。结论息风通络化瘀汤治疗高血压病(肝阳上亢兼血瘀证)疗效确切,同时能降低此类患者的超敏C-反应蛋白及血脂水平。

Efficacy and safety of Xinglouchengqi decoction for acute ischemic stroke with constipation:study protocol for a randomized con-trolled trial

OBJECTIVE: To investigate the efficacy and safety of Xinglouchengqi(XLCQ) decoction in treatment of acute ischemic stroke with constipation.METHODS: In this prospective, multicenter, assessor-blinded, randomized controlled trial, 360 eligible participants will be randomized to the XLCQ group or the control group. Participants in the XLCQ group will receive XLCQ decoction, while those in the control group will undergo clysis therapy using glycerin enemas or oral administration of lactulose solution. Both groups will undergo a treatment period of(5 ± 2) d and a 1-month follow-up.The primary outcome measure will be the Constipation Scale score. The secondary outcome measures will include scores on the National Institutes of Health Stroke Scale, the Traditional Chinese Medicine(TCM) Stroke Scale, the Diagnostic Scale for TCM Syndromes of Ischemic Stroke and TCM Scale for Syndrome of Phlegm-heat and Fu-organ Excess.Therapeutic mechanism outcomes and safety outcomes will also be assessed. Assessments will be conducted at baseline, at the end of the treatment period, and at the follow-up. Moreover, daily visits will be scheduled to grade the status of constipation during the treatment period.DISCUSSION: The results of this study will provide scientific and objective data with which to assess the efficacy and safety of XLCQ decoction for patients with acute ischemic stroke and constipation.

Differential gene expression profile of Buyanghuanwu decoction in rats with ventricular remodeling post-myocardial infarction

OBJECTIVE: To investigate the effect of Buyanghuanwu decoction(BYHWD) on gene expression in ventricular remodeling post-myocardial infarction in rats.METHODS: Animal models of myocardial infarction were established by permanent ligation of the left anterior descending coronary artery. Echocardiography measurements were performed after the treatment of BYHWD(18 g·kg-1 collagen was observ·d-1) for 90 days.Myocardialed by mallory trichrome staining. Capillary density was quantified by using Factor rentially expⅧre immunohistochemical staining.Diffessed genes were explored by a short-read sequencing technology combined with a tag-based digital gene expression profiling(DGE)system. Real-time quantitative polymerase chain reaction detecting system(q PCR) was used to validate the sequencing results. After assembling the gene information from Sham, model and BYHWD groups, we constructed three DGE libraries based on each group. The sequencing of three libraries generated 66 000-73 000 unique tags, which were mapped to reference sequences for annotation of expressed genes.RESULTS: Among them, 511 and 352 differentially expressed genes were found in comparison with sham/model and model/BYHWD, respectively. Fifty-five genes exhibited reversed direction of gene expression differences between Sham/Model and Model/BYHWD groups. We found that transforming growth factor beta receptor-1, junctophilin-2,monocyte chemotactic protein 1, neuropeptide Y,arachidonate 5-Lipoxygenase, arachidonate 15-Lipoxygenase were significantly modulated, which suggested the involvement of these genes in BYHWD treatment.CONCLUSION: The DGE profiling data provide comprehensive gene expression information at the transcriptional level that could facilitate our understanding of the pharmacological mechanisms of BYHWD in ventricular remodeling post-myocardial infarction.